Hamstring Versus Quadriceps Tendon Graft for MPFL Reconstruction

August 21, 2026 updated by: Mahmoud Ahmed El-Desouky, Cairo University

Comparison Between Hamstring Versus Quadriceps Tendon Graft in MPFL Reconstruction for Recurrent Patellar Dislocation

This prospective comparative study compared the clinical and radiological outcomes of medial patellofemoral ligament (MPFL) reconstruction using a hamstring tendon graft versus a quadriceps tendon graft in patients with recurrent patellar dislocation. The study included 38 patients with 40 affected knees who underwent MPFL reconstruction using either a hamstring tendon graft or a quadriceps tendon graft, according to the treating surgeon's preference. Patients were prospectively followed in two groups according to the graft used. Clinical outcomes were assessed using the Kujala, International Knee Documentation Committee (IKDC), and Tegner-Lysholm scores. Radiological assessment included patellar tilt angle and congruence angle. Postoperative complications and recurrent patellar instability were also evaluated.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
38

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Cairo University Hospitals (Kasr Al-Ainy)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with recurrent patellar instability who underwent medial patellofemoral ligament reconstruction using either a hamstring tendon graft or a quadriceps tendon graft.

Description

Inclusion Criteria:

  • Patients with recurrent patellar dislocation.
  • Age from 18 to 40 years.
  • Patients indicated for isolated medial patellofemoral ligament (MPFL) reconstruction.

Exclusion Criteria:

  1. Patients with trochlear dysplasia (Dejour B-C-D).
  2. Patients with clinical evidence of mal-alignment (varus, valgus, flat foot and femoral anteversion).
  3. Patients with congenital pateller dislocation.
  4. Patella alta and patella baja.
  5. Previous quadriceps muscles operation.
  6. Patients with patellofemoral OA.
  7. Patients with hypermobility syndrome.
  8. Patients with associated pathology.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Hamstring Tendon Graft Group
Patients who underwent MPFL reconstruction using a hamstring tendon graft.
Procedure: MPFL Reconstruction Using Hamstring Tendon Graft
Medial patellofemoral ligament reconstruction was performed using an autologous semitendinosus tendon graft. The graft was fixed to the medial aspect of the patella and passed between layers 2 and 3 of the medial knee structures, followed by femoral fixation at the anatomical MPFL insertion.
Quadriceps Tendon Graft Group
Patients who underwent MPFL reconstruction using a quadriceps tendon graft.
Procedure: MPFL Reconstruction Using Quadriceps Tendon Graft
Medial patellofemoral ligament reconstruction was performed using a distally based superficial quadriceps tendon graft. The graft remained attached to the superior pole of the patella, was passed between layers 2 and 3 of the medial knee structures, and was fixed at the anatomical femoral insertion of the MPFL.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Kujala score
Time Frame: 12 months postoperatively
Functional outcome assessed using the Kujala anterior knee pain scale. The score ranges from 0 to 100, with higher scores indicating better knee function and fewer patellofemoral symptoms.
12 months postoperatively

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
International Knee Documentation Committee (IKDC) Score
Time Frame: 12 months postoperatively
Knee function was assessed using the International Knee Documentation Committee (IKDC) score. Scores range from 0 to 100, with higher scores indicating better knee function.
12 months postoperatively
Tegner-Lysholm Knee Score
Time Frame: 12 months postoperatively
Knee function was assessed using the Tegner-Lysholm knee score. Scores range from 0 to 100, with higher scores indicating better knee function.
12 months postoperatively
Patellar Tilt Angle
Time Frame: 12 months postoperatively
Patellar tilt angle was measured radiologically to assess patellofemoral alignment before and after MPFL reconstruction.
12 months postoperatively
Congruence Angle
Time Frame: 12 months postoperatively
Congruence angle was measured radiologically to assess patellofemoral alignment before and after MPFL reconstruction.
12 months postoperatively
Incidence of Re-dislocation
Time Frame: 12 months postoperatively
Number of cases who experienced re-dislocation after MPFL reconstruction
12 months postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2018

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 21, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 21, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 25, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 25, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • N-356-2018

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings